Enter multiple symbols separated by commas

Novartis lifts guidance for second quarter in row


Swiss drugmaker Novartis raised its full-year outlook for a second quarter in a row on Wednesday, due to the ongoing absence of generic competition to its best-selling blood pressure pill Diovan.

The Basel-based firm now expects full-year sales to grow at a low to mid-single digit rate in constant currencies, and core earnings to be in line or better than the previous year.

It had previously guided for a low single digit decline in core earnings, and low single-digit sales growth.

Novartis lost its patent rights on Diovan in the United States last year but has so far been spared the full blow of the patent loss as U.S. regulators have not yet approved a generic version of its monotherapy from Ranbaxy Laboratories.

Novartis' net sales were up 4 percent in the third quarter to $14.338 billion, generating core earnings per shares of $1.26 billion. Analysts in a Reuters poll had forecast net sales of $14.316 billion and core EPS of $1.29.

Follow us on Twitter: @CNBCWorld

Contact Europe News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Europe Video

  • Mobile app success boosts Dominos

    David Wild, CEO of Domino's Pizza Group PLC, talks about getting involved in mobile tech, greater transparency on nutrition and expanding in Europe.

  • Will Russia hold rates on Friday?

    Joseph Dayan, head of markets at BCS Financial Group, explains why he thinks Russia's central bank will "pause and wait" when it comes to cutting interest rates.

  • Yellen has been 'crystal clear' on hikes

    Bob Parker, senior advisor of investment strategy & research at Credit Suisse, lays out expectations on how the U.S. Federal Reserve will hike rates over the next 18 months.